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Abstract- Primary growth hormone insensitivity syndrome (GHIS) is a rare entity which can be due to 
defects in growth hormone (GH) receptor that is called type 1 Laron syndrome (T1LS) or  post receptor 
defects (type 2 Laron syndrome ). The aim of study was determining the clinical and hormonal milieu 
of the patients with primary GHIS and their response to IGF-I (insulin like growth factor-I) generation 
test (IGT). GH, IGF-I, IGF-II, IGF binding protein 1 and 3 (BP-1 and BP-3), GH binding protein 
(GHBP) and anti-GH antibody were detected by ELISA and RIA methods. IGF-I and BP-3 were 
measured before and after IGT. Nine patients (8 males, 1 female) (mean age ± SD, 6.4 ± 5 years) with 
severe short stature and high GH level were studied. Height SDS was - 8.5 ± 2.6. In 7 patients GHBP 
was zero, IGF-I and BP-3 were low and did not increase after IGT, so they had T1LS. Two brothers did 
not show the hormonal milieu of GH receptor defect, and were called non Laron syndrome (NLS). Birth 
weight in patients with T1LS and NLS was 3.65 ± 0.2 Kg and 1.65 ± 0.2 Kg, respectively (P = 0.001). 
All of the patients had typical clinical feature of GH-deficiency, but nasal bridge depression and 
microphallus were not seen in NLS. GH treatment of NLS, normalized their growth velocity, but 
without catch up growth. In conclusion IGT can differentiate Laron syndrome from other types of short 
stature. GH and IGF-I of fetus have no role in intrauterine growth. 
Acta Medica Iranica, 44(1): 53-58; 2006 
© 2006 Tehran University of Medical Sciences. All rights reserved. 
 
Key words: Growth hormone insensitivity syndrome, Type 1 Laron syndrome, IGF-I generation test, 
IGF-I, IGF binding protein-3, IGF binding protein-1, IGF-II 
 
INTRODUCTION 
 
Growth hormone insensitivity syndrome (GHIS) 
can be due to polymorphic molecular defects in the 
growth hormone (GH) receptor leading to inability 
to generate endogenous insulin like growth factor-I 
(IGF-I) that is called type 1 Laron syndrome  (T1LS)  
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or to  post  receptor  defects  named  as  type 2 Laron  
syndrome (T2LS). The first report on T1LS was in 
1966 by Laron (1). These patients have typical 
clinical features of GH deficiency consisting of 
frontal bossing, nasal bridge depression and 
triangular face due to underdeveloped mandible, 
crowded teeth, high pitched voice, microphallus and 
chubby body (2). Clinical and laboratory study of 
these patients opens perspectives in the investigation 
of GH and IGFs action (2-4).  
Clinical and laboratory investigation and IGF-I 
generation test were performed in a group of  
patients with severe short stature and high GH   
level. The aim of study was determining the clinical 
Hormonal milieu of patients with GHIS 
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and hormonal milieu of the patients with primary 
GHIS and their response to IGF-I generation test (IGT). 
 
MATERIALS AND METHODS 
 
Nine patients (8 males, 1 female) were studied. 
The age of patients was from 4 months to 17.58 
years (mean ± SD) (6.4 ± 5 yr). All of the patients 
were products of consanguineous marriages and the 
parents were first cousin. They were among 21 
siblings (12 males, 9 females) belonging to 5 
families. Two of these families were relatives. 
Routine biochemical studies were done. GH was 
measured at different times of day (0700 h, 1200 h, 
1600 h and 2000 h) in the Institute of Endocrinology 
and Metabolism in Tehran with a commercial 
radioimmunoassay (RIA) kit (Spectria, Orion 
Diagnostica, Espoo, Finland). Intra assay coefficient 
of variation (CV) for 2.5 ng/mL and 40.58 ng/mL 
was 6.1% and 4.4%, respectively, and inter assay CV 
for 1.36 ng/mL and 12.5 ng/mL was 13.7% and 4% 
respectively.  
Skeletal survey was done for case 2 and 3. Bone 
age was determined by Tanner-Whitehouse method 
according to Atlas of Greulich and Pyle, and skull X-
ray was done for all of the patients. Weight height 
index (WHI, [patient weight/weight for height age] x 
100) was determined and GVI ([patients growth 
velocity/normal growth velocity for age] x 100) was 
calculated before and after treatment with GH for 
patients 2 and 3. Skin fold thickness was measured 
in different parts of body as indicator of 
subcutaneous fat tissue.  IGF-I, IGF-II, BP-1, BP-3, 
GHBP and anti GH antibody were measured as 
baseline. IGT was performed according to 
instruction of Kabi Pharmacia in a collaborative 
study as “Extended screening for definition of 
GHRD and GH-gene deletion”. IGF-I and BP-3 were 
measured at day 5 and 8 after low dose and high 
dose subcutaneous GH administration. 
 
Method of IGT 
Seven rhGH injections were given to the patients 
in the evening, during 7 consecutive days (except 
day 1 which for practical reason, were given in the 
morning). The dosages were as follow: Day 1–4, 0.1 
IU/kg/day subcutaneously (SC); day 5–7, 0.2 
IU/kg/day SC. Blood samples for measurement of 
IGF-I and BP-3 were drawn in the morning of day 1 
(pre-test), day 5 (within 12 h after the latest 
injection) and day 8 (within 12 h after the latest 
injection). The subjects were fasted for 10 hours 
before the samplings. In the morning of day 1, 
samples for measurement of GH, IGF-II, IGFBP-1, 
and GHBP and anti GH antibody were also 
provided. Blood samples were drawn into standard 
tubes without anticoagulants and left at room 
temperature > 30 minutes to coagulate except for the 
samples of GHBP that were drawn in the tubes with 
anticoagulants. After centrifugation the serum and 
plasma samples were stored in a deep freezer -70 °C 
in separate plastic tubes with specific labels until 
shipped on dry ice to Sweden by fast mail. All of 
these laboratory analyses were performed at Kabi 
Pharmacia or affiliated laboratories in Stockholm. 
These GH measurements were performed by 
immunosorbent assay (ELISA) (WHO 66/217), the 
measuring range of the assay was 0.4–12.5 mU/L. At 
concentration of 1.1 mU/L, the intraassay and 
interassay coefficients of variation (CV) were 3.0% 
and 8.0%, respectively. At 6.2 mU/L, the intraassay 
and interassay CV were 6.5% and 9.0%, 
respectively. The assay had low cross reactivity 
against hTSH (0.28%), hFSH (0.03%), hLH (< 
0.001%), hPRL (0.007%), hCG (< 0.002%) and hPL 
(0.47%). Method of measurement of IGF-I was 
competitive RIA. At a concentration of 202 ng IGF-
I/mL the intra-assay and inter-assay coefficients of 
variation were 3.1% and 10.0%, respectively. The 
IGF-I standard, DSQ 93, was an in-house standard 
calibrated against a WHO standard. The assay had a 
cross reactivity for IGF-II of about 1%. For insulin, 
proinsulin and smaller synthesized IGF-I fragments 
(1-10, 19-30, 30-40 and 57-70, respectively) the 
cross-reactivity was negligible.   
 
RESULTS 
 
The anthropometric characteristics of patients are 
illustrated in table 1. Biochemical profile and thyroid 
function tests were normal (Table 1). 
According to the results of laboratory tests, 7 
patients had T1LS and 2 brothers did not have LS 
that is called non-LS (NLS) who are patients 2 and 
3. Mean of birth weight in T1LS and NLS was 3.65 
± 0.2 Kg and 1.65 ± 0.2 Kg, respectively (P= 0.001); 
and their birth length was 48 ± 1.7 cm and 40.0 ± 0.0  
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Table 1. Anthropometric characteristics and biochemical profile of the patients 
 Patient   
Character 1 2 3 4 5 6 7 8 9 Mean SD 
Birth weight g 3200 1800 1500 3800 3750 ND 3400 ND ND - - 
Birth height cm 46 40 40 ND 49 ND 49 ND ND - - 
Chronological age 3.047 4.019 9.022 6.691 0.365 7.447 2.639 17.759 7.619 6.512 5.074 
Height at entry cm 72 71 89 79.5 54 76 67 105 81 77 14 
HSDS -7.4 -9.5 -9.67 -9.6 - 4.6 -7.6 -8.6 -10.7 -10.4 -8.45 2.6 
Weight kg 8.3 7.4 11.5 10 5.5 8.3 7.0 15.5 10 9.28 2.95 
WHI 90.2 83.1 88.5 92.6 122.2 83.0 104.5 91.2 89.3 93.84 12.35 
Bone age yr 1.5 2.5 7 2.5 0.25 2.5 0.83 9.5 2 3.18 3 
BA - HA 0.67 1.75 4.84 1.125 0.167 1.417 0.29 5.17 0.5 1.77 1.8 
Sitting height cm 40 43 54 44 34 44 40 55.5 45 44.4 6.7 
Arm Span cm 70 65 90.5 72.5 53 70 62.5 96 74.5 72.67 13.4 
Upper/Lower seg 1.25 1.53 1.54 1.24 1.70 1.37 1.48 1.12 1.25 1.38 0.19 
Arm span - height 0.69 0.66 0.70 0.72 2.40 0.60 0.75 0.82 0.62 0.89 0.57 
Biochemical profile          Normal range 
FBS mg/dL 82 76 65 76 60 70 96 70 60 60-100 
BUN mg/dL 17 12 11 15 13 10 12 13 17 5-18 
Cre mg/dL 0.6 0.6 0.4 0.5 0.3 0.5 0.6 1 0.8 0.3-0.7 
Na mEq/L 138 143 137 135 133 142 145 138 136 135-148 
K mEq/L 5.1 4.5 4.6 4.2 5 4.6 4.2 3.8 3.8 3.5-5.3 
Ca mg/dL 9.9 9.6 8.3 9.7 8.7 10 8.8 10.3 9.3 8.5-10.5 
P mg/dL 5.6 5.7 4.8 5.3 4.3 5.6 5.3 4 5.8 4.5-6.5 
Hb g/dL 12.7 11.3 11.7 10.8 10.3 12.1 11.5 10.9 11 10.5-14 
T4 µg/dL 8 11.5 9.7 6 8 8.9 7.4 7.8 6.7 4.5-13 
T3U % 26.9 28.5 26.9 25 27 32.4 29.8 28 29.4 25-35 
TSH mU/L 5.1 3.2 3.3 3.3 3.0 2.0 1.8 1.5 0.5 0.3-5.6 
FTI 2.1 3.1 2.5 3.4 2.8 2.8 2.3 3.0 1.9 1.3-4.4 
Alk P U/L 170 220 300 417 130 378 515 300 480 130-600 
Abbreviations: CA, chronological age; H, height; W, weight; WHI, weight height index; BA-HA, bone age minus height age; SH, sitting height; AS-
H, arm span minus height; U/L, upper/lower segment. 
 
cm respectively. Midparental height in T1LS and 
NLS was 167 ± 7 cm and 161 cm, respectively. WHI 
was < 100 in all of the patients except 2 patients in 
T1LS group. Bone age was more than height age in 
all of the patients.  
All of the patients had typical clinical features of 
GH-deficiency including frontal bossing, small 
mandible, and disproportionate face to skull and high 
pitched voice. Seven patients with T1LS had nasal 
bridge depression, but it was not seen in NLS, 
especially in the elder brother. Six boys with T1LS 
had microphallus, but the genitalia was normal in 
patients with NLS. Subcutaneous fat tissue was well 
developed mainly in truncal and limbs areas in 
T1LS, but was more in truncal area in NLS (Table 2).  
Table 2. Skin fold thickness of the study patients 
Patient Age BC TC (MNR) SS (MNR) SI 
1 3.047 8 13 (10) 9 (6) 8 
2 4.019 4 8 (9.5) 6 (5.5) 7 
3 9.022 7 9 (8.5) 8 (5.5) 7 
4 6.691 11 15 (8.2) 8 (5.2) 10 
5 0.365 9 11.5 (10) 9 (8) 12 
6 7.447 7 12 (9.8) 7 (6) 6.5 
7 2.639 9 13 (10.2) 13 (6) 12 
8 17.759 12 16 (8.6) 15 (9.5) 12 
9 7.619 11.5 13 (8.2) 10 (5.2) 10 
Mean 6.512 8.72 12.28 9.44 10.28 
SD 5.074 2.56 2.56 2.88 2.5 
Abbreviation: BC, biceps; TC, triceps; MNR, mean of normal range; 
SS, subscapular; SI, suprailiac.  
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Table 3. Serum GH levels (ng/mL) in different times a day and with L-Dopa test in the patients 
Patients basal P.L-dopa 7 AM 12 AM 4 PM 8 PM 
1 17.9 54.5 19.9 10.9 9.2 18.6 
2 12 20 12 2 1 2 
3 15 50 15 4.6 1.3 1.6 
4 39 55 110.5 41 14 10.5 
5 ND ND 240.6 139.3 306.3 116.3 
6 35 83 29.2 39.2 17.1 27.1 
7 31 50 29.4 17.6 20 17.5 
8 ND ND 117.9 127.9 86.5 64.2 
9 11 50 46.8 75.5 55.2 111.4 
  Abbreviation: P.L-Dopa, post L-Dopa provocative test. 
 
 
 
GH as basal and after L-Dopa provocative test 
was high in all of the patients. GH was high at 
different times a day except in patient 1 at 1600 h 
and in NLS at 1200 h, 1600 h, and 2000 h (Table 3).  
IGF-I and BP-3 were low before and after IGT, 
and GHBP was zero in T1LS. In NLS, IGF-I, and 
BP-3 rose after IGT and GHBP was detectable 
(Table 4).   
The 2 brothers with NLS were treated with 0.7 
U/kg/week divided to 7 subcutaneous injections 
before bedtime for 1 year. Growth velocity index of  
patients 2 and 3 was 55% and 57%, respectively, 
before treatment, and it increased to 91% and 100% 
respectively after treatment, but they did not have 
catch up growth.  Skeletal survey in patients with 
NLS was normal. Skull X-ray of all the patients was 
normal.  
DISCUSSION 
 
The primary GH–binding protein in humans is 
derived by proteolytic cleavage from the 
extracellular domain of the GH receptor. Therefore, 
it is not surprising that GHBP was found to be 
absent from the circulation of patients with GH 
receptor deficiency. (5-7). GHBP was zero in 7 of 
our patients, so their diagnosis was T1LS. It was 
present in patients 2 and 3 (NLS). Basal IGF-I and 
BP-3 were low in T1LS and did not rise by IGT, but 
they were normal in NLS and increased by IGT. So 
NLS had functioning GH receptor that could 
produce IGF-I and BP-3.  
NLS patients at the age of 4 and 9 yr had severe 
short stature that is evidenced from height SDS of –
9.5 and -9.67, respectively. They had normal skeletal
 
Table 4. The results of laboratory investigations and IGT in the study patients* 
IGF-I (ng/mL) BP-3 (ng/mL) 
Patient 
GH 
mU/L Pre day 5 day 8 
IGF-II 
ng/mL 
BP-I 
ng/mL Pre day 5 day 8 
GHBP 
% 
Anti 
GH 
1 30.4 <20 <20 <20 47 97 203 199 210 0 0 
2 20 51 173 247 331 35 2206 2887 4149 19.6 0 
3 46.3 227 377 371 463 19 4744 4857 4949 36.1 0 
4 32.8 <20 <20 <20 39 119 262 246 209 0 0 
5 124.7 <20 <20 <20 153 362 462 253 544 0 0 
6 113.6 <20 <20 <20 67 78 326 386 407 0 0 
7 56.1 <20 <20 <20 55 190 248 207 261 0 0 
8 24.3 <20 <20 <20 147 68 438 464 513 0 0 
9 17.9 <20 <20 <20 57 215 277 231 202 0 0 
 Abbreviations: GH, growth hormone; IGF, insulin like growth factor; BP-I and BP-3, IGF binding protein I and 3; GHBP, GH binding protein; Anti 
GH, anti GH antibody.   
*Normal values are: GH, up to 10 mU/L; IGF-I, males 197 ± 15 ng/ml and females 182 ± 14 ng/ml; BP-I, 9–47 ng/ml; BP-3,  1200–3000 ng/ml.
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survey and did not have any dysmorphic appearance 
or systemic illness. Their growth velocity 
normalized with growth hormone, but did not catch 
up growth. 
Conditions of insensitivity to IGF-I action exists 
and includes abnormalities in IGF transport and 
clearance that would alter presentation of IGF to its 
receptor (8, 9) or primary defects of IGF receptor 
production or responsiveness (10). In the African 
pygmies, a series of studies (11) demonstrated 
extreme insensitivity to the in vitro growth-
enhancing effects of IGF-I. In our study 2 patients 
had severe short stature with no special feature of 
any syndrome. IGT and laboratory investigation 
showed, that the GH receptor was present, and was 
capable of producing IGF-I and IGF-BP3. Because 
they responded to exogenous GH although not 
dramatically, it does not seem that they have IGF-I 
insensitivity, so clearing the cause of their growth 
retardation needs molecular investigations.  Patients 
with GH receptor defects that were described by 
Laron (1) have typical clinical feature of GH 
deficiency as noted in our T1LS patients, but NLS 
patients did not have microphallus and nasal bridge 
depression, so these two signs are more specific for 
GH deficiency or insensitivity. WHI was normal in 
these children but subcutaneous fat was increased so 
it is better indicator of fat accumulation in these 
children. NLS patients had normal IGF-I and low 
birth weight, but the patients with T1LS had    
normal birth weight in spite of low IGF-I, thus fetal 
IGF-I do not play an important role on fetal growth. 
 In conclusion, intrauterine growth retardation 
was not seen in patients with type 1 Laron 
syndrome. Nasal bridge depression and microphallus 
were specially seen in T1LS. Hormonal milieu and 
the response to IGT were evaluated in patients with 
severe short stature and high growth hormone.   
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